Journal article icon

Journal article

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

Abstract:

OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1016/j.ejca.2008.07.002

Authors


Carrato, A More by this author
Sobrero, A More by this author
Vincent, M More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, Clinical Lab Sciences, Biomedical Research Centre
Expand authors...
Journal:
European journal of cancer (Oxford, England : 1990)
Volume:
44
Issue:
15
Pages:
2204-2211
Publication date:
2008-10-05
DOI:
EISSN:
1879-0852
ISSN:
0959-8049
URN:
uuid:622d6222-6f1c-4ae4-a303-1022cfdc829b
Source identifiers:
346515
Local pid:
pubs:346515

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP